Unknown EARLY_PHASE1 INTERVENTIONAL 6-arm NCT03957720

The Individual Therapy for Patients With Wilson's Disease

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Interventions DMPS DMSA Penicillamine Zinc gluconate

Updated 6 times since 2019 Last updated: May 19, 2019 Started: Mar 15, 2019 Primary completion: Dec 31, 2024 Completion: Dec 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Wilson's Disease and is currently ongoing. Second Affiliated Hospital, School of Medicine, Zhejiang University leads this study, which shows 6 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Study Description(click to expand)

The purpose of the study is to evaluate treatment regimen efficacy based on different mutations, and Zinc treatment in presymptomatic WD patients.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Unknown EARLY_PHASE1
Feb 2025 — Present [monthly]

Unknown EARLY_PHASE1

Status: Recruiting → Unknown
Sep 2024 — Feb 2025 [monthly]

Recruiting EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting EARLY_PHASE1
Jan 2021 — Jul 2024 [monthly]

Recruiting EARLY_PHASE1

▶ Show 1 earlier version

Jun 2019 — Jan 2021 [monthly]

Recruiting EARLY_PHASE1

First recorded

Mar 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Second Affiliated Hospital, School of Medicine, Zhejiang University

Data source: Second Affiliated Hospital, School of Medicine, Zhejiang University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China